Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2699-2704

  Weiss, Brendan M ^a   Hebreo, Joseph ^b   Cordaro, Daniel V ^c   Roschewski, Mark J ^c   Baker, Thomas P ^c   Abbott, Kevin C ^c   Olson, Stephen W ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; PLASMA PROTEIN;

ADULT; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; ELECTROPHORESIS; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; MALE; PRIORITY JOURNAL; RACE; SERUM; SEX; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AMYLOIDOSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84906807379     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.0892     Document Type: Article

References (33)

1. Merlini G, Stone MJ: Dangerous small B-cell clones. Blood 108:2520-2530, 2006
2. Kumar SK, Gertz MA, Lacy MQ, et al: Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clinic Proc 86:12-18, 2011
3. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215-224, 2009
4. Katzmann JA, Abraham RS, Dispenzieri A, et al....: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51:878-881, 2005
5. Weiss BM, Abadie J, Verma P, et al: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418-5422, 2009
6. Landgren O, Kyle RA, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 113:5412-5417, 2009
7. Dispenzieri A, Katzmann JA, Kyle RA, et al: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet 375:1721-1728, 2010
8. Niven DJ, Berthiaume LR, Fick GH, et al: Matched case-control studies: A review of reported statistical methodology. Clin Epidemiol 4:99-110, 2012
9. Olson SW, Arbogast CB, Baker TP, et al: Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22:1946-1952, 2011
10. Comenzo RL: How I treat amyloidosis. Blood 114:3147-3157, 2009
11. Katzmann JA, Clark RJ, Abraham RS, et al: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437-1444, 2002
12. McNemar Q: Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153-157, 1947
13. Kumar S, Dispenzieri A, Lacy MQ, et al: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989-995, 2012
14. Kumar SK, Dispenzieri A, Lacy MQ, et al: Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86:251-255, 2011
15. Olson SW, Lee JJ, Prince LK, et al: Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin J Am Soc Nephrol 8:1702-1708, 2013
16. Olson SW, Owshalimpur D, Yuan CM, et al: Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis. Clin J Am Soc Nephrol 8:1312-1318, 2013
17. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 78:21-33, 2003
18. Korde N, Kristinsson SY, Landgren O: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood 117:5573-5581, 2011
19. Comenzo RL, Zhang Y, Martinez C, et al: The tropism of organ involvement in primary systemic amyloidosis: Contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 98:714-720, 2001
20. Perfetti V, Casarini S, Palladini G, et al: Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloidassociated germline gene segment. Blood 100:948-953, 2002
21. Perfetti V, Palladini G, Casarini S, et al: The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119:144-150, 2012
22. Bladé J, Rosiñol L, Cibeira MT, et al: Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22: 1651-1657, 2008
23. Kyle RA, Therneau TM, Rajkumar SV, et al: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569, 2002
24. Cohen AD, Comenzo RL: Systemic light-chain amyloidosis: Advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010:287-294, 2010
25. Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003
26. Gertz MA, Li CY, Shirahama T, et al: Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Intern Med 148:929-933, 1988
27. Merlini G, Palladini G: Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012:595-603, 2012
28. Fonseca R, Bailey RJ, Ahmann GJ, et al: Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100:1417-1424, 2002
29. Paiva B, Vídriales MB, Pé rez JJ, et al: The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 117:3613-3616, 2011
30. Fonseca R, Ahmann GJ, Jalal SM, et al: Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 103:704-710, 1998
31. Bochtler T, Hegenbart U, Cremer FW, et al: Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 111:4700-4705, 2008
32. Greene MJ, Sam F, Soo Hoo PT, et al: Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol 178:61-68, 2011
33. Palladini G, Barassi A, Perlini S, et al: Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 18:216-221, 2011